ClinicalTrials.gg
RecruitingNCT05454267ENDSUpdated May 15, 2026

Early Detection of Vaping-related Vascular Diseases

An observational study in Vaping and Blood Vessel Injury, sponsored by University of Miami. Recruiting at 1 site in United States. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by University of Miami · Observational

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 1 month later.
Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
90
Ages
18 Years to 40 Years
Sex
All
01

Study summary

The purpose of this study is to determine how vaping affects blood vessels, in particular if early damage occurs in the lung vessels.

02

Conditions studied

  • Vaping
  • Blood Vessel Injury
03

In context

Vaping

402 studies on the registry are indexed under Vaping; 95 are open to participants now.

This study's planned enrollment of 90 is below the median of 120 across 65 observational studies indexed under Vaping.

Browse Vaping studies →

Lead sponsor

University of Miami is the lead sponsor of 840 studies on the registry; 164 are open to participants now.

Of its 115 completed or terminated interventional studies of FDA-regulated products, 97 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy non smokers and vapers residing in Florida

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Vapers Group:

  1. Current electronic cigarette (EC) Puff Bar users defined as using EC either daily or occasionally in the past 30 days for at least 6 months, and with 5% nicotine concentration pods.
  2. Adults aged 18-40 years

Healthy Group:

  1. Healthy never smokers, never vapers
  2. Adults aged 18-40 years

Exclusion criteria

Exclusion Criteria:

  1. Current or past smoking of tobacco cigarette (TC) or other tobacco/nicotine products (e.g., smokeless tobacco, Hookah) or marijuana will be excluded from the study.
  2. Subjects with self-reported history of chronic health problems including asthma, (COPD), morbid obesity (>40 kg/m2), hypertension or diabetes
  3. Pregnant or breastfeeding women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
90 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Healthy Volunteer Group

    Participants who have never smoked or vaped

  • High Frequency Vaping Group

    Participants who vape \>20 days per month.

  • Low-Frequency Vaping Group

    Participants who vape \< 20 days per month

06

What researchers measure

Primary outcomes

  1. Airway blood flow reactivity (QAW)

    QAW will be measured via soluble gas uptake method

    Time frame: Up to 1 week

  2. Pulmonary vascular resistance (PVR)

    PVR will be measured via echocardiography

    Time frame: Up to 4 weeks

  3. Flow-mediated vasodilation (FMD)

    FMD will be measured by blood pressure cuff deflation using ultrasound

    Time frame: Up to 4 weeks

07

Study locations

1 of 1 sites recruiting
  • University of Miami Health System
    Miami, Florida 33136, United States
    Recruiting
    • Michael Campos, MD · Contactmcampos1@med.miami.edu · 3052436388
    • Adam Wanner, MD · Principal investigator
    • Michael Campos, MD · Sub investigator
    • Barry Hurwitz, MD · Sub investigator
    • Taghrid Asfar, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05454267
Collaborators
Florida Department of Health
Responsible party
Adam Wanner (Professor of Medicine, University of Miami) — Principal investigator
First posted
Jul 12, 2022
Start date
Sep 12, 2022
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 15, 2026

Study contacts

Adam Wanner, MD
Contact
awanner@med.miami.edu
(305)243-2568
Michael Campos, MD
Contact
mcampos1@med.miami.edu
3052436388
Adam Wanner, MD
principal investigator · University of Miami

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion